Related references
Note: Only part of the references are listed.Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry
Frederick Lansigan et al.
ACTA HAEMATOLOGICA (2020)
Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
Dai Maruyama et al.
ANNALS OF HEMATOLOGY (2019)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry
Robert N. Stuver et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Monica Bellei et al.
HAEMATOLOGICA (2018)
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Monica Bellei et al.
HAEMATOLOGICA (2018)
Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study
Owen A. O'Connor et al.
JNCI CANCER SPECTRUM (2018)
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
Dai Chihara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
Y. Shi et al.
ANNALS OF ONCOLOGY (2015)
Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission
Manish Sharma et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
Norbert Schmitz et al.
BLOOD (2010)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
